arrow
L

Luigi Mariani

university of basel
H指数:102
被引数:4.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials

将无进展生存比作为精准肿瘤学临床试验的主要终点进行基准测试

2025-12-150
OAAI
Dietary intervention for tertiary prevention in head and neck squamous cell carcinoma survivors: clinical and translational results of a randomized phase II trial
2024-01-040
OAAI
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors

外周血淋巴细胞预测接受CDK4/6抑制剂治疗的激素受体阳性HER2-negative晚期乳腺癌患者的临床结局

2023-12-201
OAAI
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2

二甲双胍联合兰瑞肽治疗晚期胃肠道或肺神经内分泌肿瘤的安全性和抗肿瘤活性: Ib期试验MetNET2

2023-12-140
OAAI
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
2023-04-1715
OAAI
HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy
2023-03-013
PRE
Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses

晚期乳腺叶状肿瘤的系统治疗: 一项多机构欧洲回顾性病例系列分析

2022-02-129
OA
Uterine serous carcinoma: role of surgery, risk factors and oncologic outcomes. Experience of a tertiary center

子宫浆液性癌: 手术的作用,危险因素和肿瘤学结果。三级中心的经验

EJSO
IF2.9
2022-01-012
PRE
A phase II trial of induction chemotherapy (IC), photon-, proton- and carbon ion-based radiotherapy (RT) integration in locally advanced inoperable sinonasal epithelial tumors patients (pts)
2021-09-010
OAAI